Zenas Biopharma, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Zenas BioPharma is increasing its IPO offering size by registering additional shares worth approximately $28.8 million, including an option for underwriters to purchase more shares.
NASDAQ
Zenas BioPharma, a clinical-stage biopharmaceutical company, is seeking to raise $180.7 million through an initial public offering to advance its immunology-based therapies.
NASDAQ
Zenas BioPharma amends its license agreement with Xencor and files an S-1 registration statement for an initial public offering of its common stock.